When was Aucta Pharmaceuticals founded?

Aucta Pharmaceuticals was founded in 2012 and raised its 1st funding round 3 years after it was founded.

Where is Aucta Pharmaceuticals located?

Aucta Pharmaceuticals is headquartered in New Brunswick, United States.

Who is the current CEO of Aucta Pharmaceuticals?

Shoufeng Li of Aucta Pharmaceuticals.

How many employees does Aucta Pharmaceuticals have?

As of Jun 30, 2026, the latest employee count at Aucta Pharmaceuticals is 69.

Is Aucta Pharmaceuticals a funded company?

Aucta Pharmaceuticals is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Nov 2015.

When was the latest funding round of Aucta Pharmaceuticals?

Aucta Pharmaceuticals' latest funding was a $***** Seed round on Nov 2015, with participation from 1 investor.

Where does Aucta Pharmaceuticals rank among its competitors?

Aucta Pharmaceuticals ranks 58th amongst 964 active competitors, of which 42 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Nivagen Pharmaceuticals, which secured $5M in Aug, 2023.

Who are the top competitors of Aucta Pharmaceuticals?

Aucta Pharmaceuticals' top competitors include Jubilant Life Sciences, Akums and HitGen. Among them, Nivagen Pharmaceuticals secured the most recent funding round in August, 2023.

Aucta Pharmaceuticals - 2026 Company Profile, Team, Funding & Competitors

Company Details

Innovating enhanced therapeutics using technology for specialty brand and generic products. This is a technology-based pharmaceutical company focused on developing and commercializing specialty brand and specialty generics products. It creates better products from proven molecules, utilizing innovative approaches to develop new therapeutics, including new dosage forms, dosing regimens, and indications. The company focuses on central nervous system and orphan indications, leveraging technology platforms such as pediatric formulations, controlled release systems, and novel delivery methods. Committed to being patient-centric, it continuously brings improved forms and patient-centric service platforms of specialty products to the marketplace. The company operates in both the United States and China. The business model is focused on pharmaceutical innovation, research and development, and commercialization of improved medicines.

Website: auctapharma.com
Email ID: *****@auctapharma.com

Key Metrics

Founded Year

2012

Location

New Brunswick, United States

Stage

Seed

Latest Funding Round

Seed, Nov 2015, $*****

Investors

Shanghai Changjiang Guohong Investment Management & 4 more

Ranked

58^th among 964 active competitors

Employee Count

69 as on Jun 30, 2026

Similar Companies

HitGen & 95 more

View Aucta Pharmaceuticals' full profile

Aucta Pharmaceuticals has raised funding over 1 round. Its latest funding round was a Seed round on Nov 2015 for $*****. 1 investor participated in its latest round. Aucta Pharmaceuticals has 5 institutional investors.

Here is the list of recent funding rounds of Aucta Pharmaceuticals:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 2015	4198445	Seed	6466540	7406326	8986483	8453574

Access funding benchmarks and valuations. Sign up today!

View details of Aucta Pharmaceuticals's funding rounds and investors

The founders of Aucta Pharmaceuticals is Shoufeng Li.

Here are the details of Aucta Pharmaceuticals' key team members:

Shoufeng Li: Co-Founder & CEO of Aucta Pharmaceuticals.
Contact Info: 1 email address

View details of Aucta Pharmaceuticals's Founder profiles and Board Members

Aucta Pharmaceuticals' employee count trend

Aucta Pharmaceuticals has 69 employees as of Jun 26. Here is Aucta Pharmaceuticals's employee count trend over the years:

Employee count trend for Aucta Pharmaceuticals

Uncover Aucta Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Aucta Pharmaceuticals include Jubilant Life Sciences, Akums and HitGen. Here is the list of Top 10 competitors of Aucta Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jubilant Life Sciences 1978, Noida (India), Public	Company offering a suite of R&D and manufacturing services for small molecules and generics	-	Samena Capital, General Atlantic & 1 others	59/100
2nd	Akums 2004, Delhi (India), Public	CDMO focusing on spectrum of dosage forms and therapeutic segments	$70M	Quadria Capital & 5 others	58/100
3rd	HitGen 2012, Lanzhou (China), Public	Developer of DNA encoded libraries for drug discovery	$39.1M	CDH, Shiyu & 2 others	57/100
4th	Nivagen Pharmaceuticals 2009, Sacramento (United States), Acquired	Developer and contract manufacturer of generic drugs, tablets, capsules, ointment and solution	$31M	Telegraph Hill Partners, BizCap & 1 others	57/100
5th	Slingshot Bioscience 2012, Berkeley (United States), Series A	Developer of next-generation synthetic cells for diagnostics and therapeutics	$46.4M	Northpond Ventures, Arch Venture Partners ... & 2 others	56/100
6th	Nectar Lifesciences 1995, Chandigarh (India), Public	Manufacturer of cephalosporin APIs and generic formulations	$46.9M	Vedanta Capital, NSR Partners & 1 others	55/100
7th	Recipharm 1995, Jordbro (Sweden), Acquired	Contract services for pharmaceutical development and manufacturing	-	CPP Investments, Ampersand Capital	54/100
8th	Supriya Lifescience 2008, Mumbai (India), Public	Manufacturer of active pharmaceutical ingredients and finished dosage formulations for healthcare	-	-	54/100
9th	Labiana 1958, Corbera de Llobregat (Spain), Unfunded	Contract laboratory and contract manufacturing services for pharmaceutical and animal health industries	-	-	54/100
10th	Chugai Pharmaceutical 1925, Tokyo (Japan), Acquired	Developer of innovative pharmaceutical products and services	-	Digital Pharma Lab	54/100
58th	Aucta Pharmaceuticals 2012, New Brunswick (United States), Seed	Innovating enhanced therapeutics using technology for specialty brand and generic products	-	SDIC Venture Capital Management, Shanghai Changjiang Guohong Investment Management ... & 3 others	42/100